All Posts

by Vista Partners LLC November 9, 2025

Obesity Drug Gold Rush: Pfizer Outbids Novo Nordisk for Metsera’s Promising Pipeline -( $PFE $MTSR $NVO $IBB $XBI )

Pfizer, never one to miss a raucous game of pharmaceutical musical chairs, has outmaneuvered Novo Nordisk in a $10 billion dash for Metsera, a company that—at the time of acquisition—boasted more promising obesity drugs in its pipeline than products on pharmacy shelves. In a market suddenly obsessed with “weight loss” instead of “blockbuster cholesterol lowering,” this deal signals Pfizer’s not-so-subtle effort to slim down its pandemic waistline while fattening up its pipeline.

A Slimmer Strategy

Metsera, the belle of this biotech ball, is a development-stage firm with no marketed products and a covetable portfolio of oral and injectable obesity treatments. Wall Street has tracked this drama like a binge-worthy miniseries: Metsera’s board cited antitrust risk in Novo Nordisk’s aggressive counter-offer, finally deeming Pfizer’s combination of cash and contingent value rights—totaling up to $86.25 a share—the “best transaction for shareholders, both in value and certainty of closing”.

Why the Rush?

The rationale is clear: Pfizer has been seeking a worthy comeback after discontinuing its own oral obesity candidate earlier this year. With Novo Nordisk and Eli Lilly vacuuming up market share with Ozempic and Wegovy, Pfizer needed a bold move to stay relevant. As CEO Albert Bourla noted, the deal “propels Pfizer into this key therapeutic area”—and, presumably, gives management one less thing to fret about at the next earnings call.

Novo’s Burning Calories

This was hardly a sleepy negotiation. Novo Nordisk raised its bid to as much as $10 billion after Pfizer’s opening play. At one point, lawsuits were flung like dumbbells at a press junket. Ultimately, Metsera’s board went with the acquirer least likely to trigger prolonged regulatory review—a decision more about legal metabolism than romance.

Pipeline: More Than Just Empty Calories

Metsera brings to Pfizer four late-stage clinical programs, including oral and injectable GLP-1 receptor agonists and amylin analog treatments aimed at monthly dosing, durability, and, just maybe, a world where weight loss drugs require less frequent injections than holiday feasts. In an industry where “pipeline” is often synonymous with “patience required,” Pfizer’s $10 billion bet is a reminder that big pharma will always chase the next big thing—ideally one that shrinks waists and grows wallets.

Shareholder Weigh-In

At last look, Pfizer shares traded just under $25, reflecting both investor optimism and skepticism—the kind of mixed reaction usually reserved for gym memberships on New Year’s Day. But with $10 billion on the line (and Novo Nordisk left holding its salad fork), Wall Street and waistlines alike will be watching to see if this deal delivers results with staying power, or just another yo-yo in the saga of pharmaceutical innovation.

The Sources

[1] Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk https://finance.yahoo.com/news/pfizer-clinches-deal-obesity-drug-173412068.html
[2] Pfizer clinches deal for obesity drug developer Metsea after a … https://abcnews.go.com/Business/wireStory/pfizer-clinches-deal-obesity-drug-developer-metsea-after-127337193
[3] Pfizer beats out Novo in bidding war for obesity-drug startup Metsera https://www.statnews.com/2025/11/07/pfizer-beats-novo-nordisk-to-acquire-metsera-obesity/
[4] Pfizer clinches deal for obesity drug developer Metsea after … – Yahoo https://www.yahoo.com/news/articles/pfizer-clinches-deal-obesity-drug-173412412.html
[5] Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-metsera-and-its-next-generation-obesity
[6] This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is … https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc
[7] Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle https://finance.yahoo.com/news/novo-nordisk-offers-6-5-103104241.html
[8] Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio https://finance.yahoo.com/news/pfizer-acquire-metsera-next-generation-104500228.html
[11] Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal https://www.nytimes.com/2025/11/08/business/metsera-pfizer-merger-weight-loss.html
[12] Pfizer wins $10 billion bidding war for obesity drug developer https://nypost.com/2025/11/08/business/pfizer-wins-10-billion-bidding-war-for-metsera-over-novo-nordisk/
[13] Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition https://www.foxbusiness.com/fox-news-health/pfizer-wins-10b-bidding-war-obesity-drug-developer-metsera-major-pharmaceutical-acquisition
[14] Pfizer wins $10bn bidding war for weight-loss start-up Metsera https://www.ft.com/content/d9f58a26-5395-4acb-8dfc-d55cb53f946e
[15] Trump strikes deal to lower cost of Wegovy, Zepbound weight loss drugs https://www.nbcnews.com/health/health-news/trump-weight-loss-drugs-cost-wegovy-zepbound-novo-nordisk-eli-lilly-rcna242309
[16] Trump unveils deals to lower US weight-loss drug prices https://www.bbc.com/news/articles/czxk7k9nd11o
[17] Pfizer, Flagship return to obesity as part of 10-program collab https://www.fiercebiotech.com/biotech/pfizer-flagship-return-obesity-part-latest-additions-multibillion-dollar-collaboration
[18] Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion … https://finance.yahoo.com/news/pfizer-jumps-weight-loss-drug-125745662.html
[19] Pfizer – ProFound Therapeutics https://www.profoundtx.com/news-and-events/flagship-and-profound-announce-agreement-under-strategic-partnership-with-pfizer
[20] Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet https://finance.yahoo.com/video/pfizer-buy-metsera-4-9-163254233.html
[21] Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 … https://finance.yahoo.com/news/pfizer-discusses-drug-pricing-deal-162800100.html
[22] Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist

by Vista Partners LLC November 7, 2025

S&P Slides and Tech Tumbles: Wall Street’s November Nerves Unveiled -( $BLLN $INTC $LLY $MODD $VIX Rise!)

Wall Street’s week wrapped with less of a bow and more of a sigh, as major indexes retreated under a cloud of AI valuation skepticism, limp labor data, and Capitol Hill’s existential drama over the government shutdown, which cost the economy an estimated $16 billion—proving that even in politics, time is, in fact, money. Indeed, Wall Street’s latest act ended with uncertainty rather than jubilation. The pros are bracing for more volatility and, as always, waiting for the next act—with popcorn ready and a P/E ratio calculator in hand.

Major Index Performance

The tech-favored Nasdaq Composite bore the brunt, tumbling 3.04% over the last 5-days for its worst spell since March, closing at 23,004.54. The S&P 500 shed 1.63% to settle at 6,728.80, and the Dow Jones Industrial Average followed its blue-chip peers downward falling 1.21% to 46,987.10. The Russell 2000, a bellwether for small caps, joined the correction chorus as investors rotated away from speculative growth falling 1.88% to 2,432.82. The markets “fear index” The Vix closed at $19.08, +9.40% over the last 5-days.

Macroeconomic Reports

The U.S. labor market delivered more hand-wringing than high-fives, with initial jobless claims inching up to 246,000 and October hiring painted as neither hot nor cold—a market porridge unable to please anyone. ISM Manufacturing PMI shrank to 48.7, while consumer sentiment hit a three-and-a-half-year nadir, a malaise attributed to the government shutdown casting a pall over the economy.

Index Movers: Sectors and Stocks

The AI “Magnificent Seven” turned into the “Meh-gnificent Several.” Nvidia (NVDA) lost 7.08% over the last 5-days, spooked by both government reluctance to bail out the AI sector and China competition comments. Apple (AAPL), ever the calm in any storm, posted usual resilience but was ultimately dragged by sector sentiment edging down .70% to $268.47. Tesla dropped 5.92% over the last 5-days, while Elon Musk’s $1 trillion pay spectacle got approved. Broadcom (AVGO) skidded 5.46% to close on Friday at $349.43, and Meta lost about 4.11% over the last 5-days to end at $621.71 amid broader tech routs. Intel, the unexpected contrarian hero, managed a 2.39% gain over the last 5-days to end at $38.13, aided by Musk’s musings that Tesla may go steady with Intel’s chip foundries in its pursuit of autonomous vehicle glory. Palantir, despite posting a blowout quarter (EPS: $0.21 vs $0.17 expected), cratered about 11.24% over the lat 5-days to end at $177.93 as “Big Short” legend Michael Burry wagered big against it and AI exuberance deflated.

Eli Lilly rose a meaty 7.13% over the last 5-days to end at $924.37 after agreeing to U.S. pressure to cut GLP-1 drug prices—short-term pain for potential long-term market dominance, analysts wager. Oklo stumbled nearly 15.15% over the last 5-days, but remains up +430.62% YTD. Opendoor Technologies (OPEN) delivered Q3 earnings—strong on vision, faint on results, with shares little moved as Wall Street digests its tech-real-estate hybrid pitch and the stock was off 15.57% over the last 5-days ending at $6.56, but up +310% YTD.

Nokia, McDonald’s, Rio Tinto, and Oracle each experienced sector-led declines, with no earth-shaking headlines to offset the selling pressure pervasive across global equities this week.

Welcomed IPOs

It was a busy week for dealmakers and debutantes. BillionToOne (NASDAQ: BLLN) completed a $314M IPO at $60 and ended the week at $100.03, Tailwind 2.0 Acquisition Corp began trading as TDWDU, and Crown Reserve Acquisition Corp. I (CRACU) launched a $150M SPAC on Nasdaq. Harvard Ave Acquisition Corp. (HAVAU) priced its $145M IPO, also starting on the NYSE.

Tariffs and Trade

Updates on U.S.-China tariffs remained subdued this week; however, headline risk is back on the menu as politicians jostle for posturing points in the shadow of the ongoing shutdown, and no further escalation or de-escalation of trade duties was announced.

Yield Curve, Rates, and Fed Announcements

Amid the shutdown, the Fed’s “fog” on policy outlook thickened, but the yield curve steepened modestly on weaker data and haven demand. The FOMC did not convene this week, but traders are tuned to the upcoming meeting, where Powell’s every syllable will be scrutinized as if it’s the Rosetta Stone of monetary policy. The 2-yr treasury ended at 3.564% & the 10-yr ended at 4.103%.

Gold, Silver, Oil, and Crypto

When Main Street gets nervous, Gold resumes its familiar role as therapist, posting modest gains closing back above $4k at $4,009.60/oz. Silver tracked gold’s mood closing at $48.24/oz., while oil prices stabilized after a bumpy ride amid geopolitical headlines closing at $59.79 and down 2.06% over the last 5-days. Bitcoin’s price moved in sympathy with risky tech but was notably more resilient, shedding less than major equities trading at $103,828.79 Friday afternoon; crypto-related stocks largely declined, led by risk-off shifts but offset by some short-covering into Friday.

Conclusion

Wall Street’s latest act ended with uncertainty rather than jubilation. The pros are bracing for more volatility and, as always, waiting for the next act—with popcorn ready and a P/E ratio calculator in hand.bloomberg+21

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.52, +5.05% over the last 5-days), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR) and M2i Global, Inc. (MTWO) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.91 stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.29) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 7, 2025

The $18 Billion Oracle AI Bet: Data Centers, Bank Syndicates, and the Future of Cloud Computing -( $ORCL $GS $MUFG $AMZN $GOOG $MSFT )

A consortium of 20 major banks has just written an $18 billion check—no, that’s not a misprint—to help underwrite Oracle’s (ORCL) latest ambition: a sprawling data center campus in New Mexico that promises to give even the most jaded AI skeptic a jolt of digital optimism, or perhaps a caffeine substitute. Administrative heavyweights—Goldman Sachs (GS), Sumitomo Mitsui Banking Corp, BNP Paribas, and Mitsubishi UFJ Financial (MUFG)—are herding institutions into what’s being dubbed a “retail syndication,” where the debt will soon be sliced, diced, and distributed like so many high-tech hors d’oeuvres for late November consumption.

Oracle Bets Big, Again

Oracle, ever the goliath with a flair for audacious finance, is expected to be the main tenant for this campus, which insiders say is a jewel of the Stargate project, an AI infrastructure initiative also tied to the likes of OpenAI and SoftBank. This all-in wager on AI is, depending on your perspective, either bold leadership or an adrenaline-pumping spin at the Silicon Valley roulette wheel. As Oracle muscles into data-center arms races with established titans like Amazon’s AWS (AMZN), Google Cloud (GOOG), and Microsoft Azure (MSFT), the company’s debt profile has ballooned to the point where even sophisticated bond traders are sipping Maalox.

Financial Alchemy and Syndicate Swagger

The assembly of banks is pitching this loan as a classic project finance gambit, the sort beloved by those who wear navy suits and understand what a Piotroski F-Score is (Goldman Sachs, in particular, would like you to know its score remains robust even as it dives deeper into stable fee-based ventures). Once the ink dries, these banks plan to syndicate the debt, an act not unlike inviting the neighbors over to help finish a particularly ambitious Thanksgiving turkey—everyone gets a share, and no one wants indigestion.

AI Boom: Promise and Risk

How much debt is “too much” in the pursuit of AI-fueled greatness? Oracle apparently believes “more,” as analysts warn the company’s total obligations could approach $290 billion by 2028—enough to buy several small countries, or at least corner the global supply of ironic headlines. Meanwhile, investors keep one eye on AI’s growth metrics, and the other on Oracle’s swelling credit-default swap spreads, just in case the rocket-fueled ride gets bumpy.

Market Reaction: Stocks, Swaps, and Sarcasm

In the grand tradition of Wall Street overcorrections, Oracle’s stock has been whipsawed, while credit-default swaps on its debt now flirt at two-year highs, signaling a chilly breeze over the company’s hot AI narrative. The strategic implication? While the coffee-fueled optimism of “big data” remains, investors can’t help but wonder if too many financiers at one table is a sign of confidence, or simply a fire code violation waiting to happen.

Certainly, for Oracle and its syndicate of enablers, this $18 billion bet is the financial equivalent of parachuting into the AI wild west wearing a suit, clutching a term sheet, and hoping the future has decent Wi-Fi.

The Sources

https://www.bloomberg.com/news/articles/2025-11-07/banks-lend-18-billion-for-oracle-tied-data-center-in-new-mexico

https://finance.yahoo.com/news/banks-lend-18-billion-oracle-202012978.html

https://www.gurufocus.com/news/3196227/goldman-sachs-gs-part-of-18b-loan-for-data-center-development

https://finance.yahoo.com/news/banks-lend-18-billion-oracle-190833906.html

https://www.moomoo.com/news/post/61157456/around-20-banks-are-in-the-queue-to-provide-an

https://www.reuters.com/business/finance/five-debt-hotspots-ai-data-centre-boom-2025-11-05/

https://economictimes.com/news/international/us/oracle-default-fears-surge-as-credit-swaps-spike-to-2-year-high-is-ai-taking-its-toll/articleshow/125065038.cms

https://www.cnbc.com/2025/11/07/time-to-snap-up-oracle-now-down-more-than-30percent-in-past-two-months-says-carter-worth.html

https://www.marketscreener.com/news/banks-lend-18-billion-for-oracle-tied-data-center-project-bloomberg-news-reports-ce7d5fdad188f72d

https://www.reuters.com/business/finance/banks-lend-18-billion-oracle-tied-data-center-project-bloomberg-news-reports-2025-11-07/

https://www.computing.co.uk/news/1836465/usd103bn-oracle-acquisition-peoplesoft-confirmed

https://www.ifre.com/people-and-markets/2338177/go-big-or-go-home-why-corporate-debt-raisings-are-getting-bigger

https://www.marketbeat.com/instant-alerts/filing-1275-shares-in-oracle-corporation-orcl-acquired-by-grey-fox-wealth-advisors-llc-2025-11-07/

https://money.usnews.com/investing/news/articles/2025-11-07/banks-lend-18-billion-for-oracle-tied-data-center-project-bloomberg-news-reports

https://www.aol.com/articles/advice-dont-distracted-oracle-stocks-092500751.html

https://www.informationweek.com/it-sectors/oracle-buying-stellent-for-440-million

https://www.datacenterdynamics.com/en/news/oracle-takes-on-18bn-in-debt-ahead-of-ai-data-center-build-out/

https://www.prnewswire.com/news-releases/oracle-and-ci4cc-partner-to-accelerate-oncology-innovation-302608712.html

https://www.oracle.com/news/

https://www.marketbeat.com/instant-alerts/filing-ethos-financial-group-llc-acquires-3911-shares-of-oracle-corporation-orcl-2025-11-07/

by Vista Partners LLC November 7, 2025

JFrog’s Earnings Leap: Hopping Past Wall Street’s Cloud Rev Forecasts (and Competitors) – ( $FROG $SPY )

JFrog’s (FROG) third-quarter 2025 performance was anything but amphibious—unless “leaping” counts. The company vaulted past Wall Street forecasts, croaking out revenue of $139.6 million, soaring 26% year-over-year and leaving analysts’ modest predictions somewhere in the lily pads. Investors had reason to rejoice; shares hopped upward by more than 24% on earnings day, hitting an all-time high like a frog chasing flies at a summer barbecue.

Financial Highlights

JFrog achieved an earnings-per-share of $0.22, a 37.5% positive surprise versus forecasts—a feat that would impress even the most skeptical of market biologists.
Cloud revenue leapt by 50% over the year, now accounting for nearly half of total revenue, reflecting the ongoing migration to cloud as the modern software pond of choice.
Gross margins of 83.9% and a net dollar retention of 118% hint at strong customer loyalty—perhaps attributable to the company’s security and AI model delivery innovations, such as the new AppTrust and AI Catalog offerings.

Market Reaction and Outlook

Market participants reacted as if someone had dropped coffee into their pond: JFrog’s stock price surged, with analyst price targets quickly being revised upward—Truist Securities, for instance, hopped from $55 to $70 basically overnight. Year-to-date, shares have climbed 60%, making it one of tech’s more energetic performers. The company now forecasts full-year revenue between $523 million and $525 million, over $15 million higher than prior estimates—a signal that management expects continued upstream swimming even if macroeconomic waters get choppy.

Strategic Moves and Sophisticated Punchlines

Alongside the numbers, JFrog demonstrated it isn’t just playing leapfrog with competitors; it’s investing heavily in secure software delivery and AI integration. The poetic irony? While risk and volatility are the bane of every software supply chain, JFrog’s Riskified acquisition and product expansion suggest it’s building a moat, not a puddle.

For now, JFrog has managed to show that not all software frogs are destined for research labs—some get to sit proudly atop their pedestal, making competitors green (with envy, naturally).

The Sources

by Vista Partners LLC November 6, 2025

Tesla Shareholders Greenlight Elon Musk’s $1 Trillion Pay Jackpot—World’s First Trillionaire in the Making? -( $TSLA $SPY )

Tesla (TSLA) shareholders have given a resounding nod to CEO Elon Musk’s audacious $1 trillion pay package, a deal so outsized it makes the GDPs of small nations seem quaint by comparison. Approved by more than 75% of voters at the company’s annual meeting in Austin, this package has the potential to make Musk the world’s first trillionaire—assuming, of course, that Tesla achieves a perfect storm of self-driving cars, robotic armies, and a stock market valuation that could buy several planets.

The Magnitude of Musk’s Windfall

The newly approved plan comes with all the dramatic trappings one expects from the world’s most headline-hungry CEO. Musk’s payday—aggregating to up to $1 trillion over ten years—is staked on a series of almost Herculean targets: boosting Tesla’s valuation far beyond its current $1.4 trillion, ramping up robotaxi fleets, and launching a veritable army of Optimus robots. One can’t help but wonder if the next shareholder proposal will involve colonizing Mars in time for spring earnings.

Boardroom High Wire, Shareholder Showmanship

Tesla’s chair Robyn Denholm warned shareholders that without such an outsized incentive, Musk might wander off to develop sentient toasters or at least focus his creative energy outside the company—an argument that clearly struck a chord with investors, many of whom seem less afraid of high executive pay than of a Musk mid-life crisis. Not everyone is waxing poetic about corporate ambition, however: opposition from Norway’s sovereign wealth fund and proxy advisors—not to mention a pope—underscores that not all are charmed by Musk’s vision or his negotiation tactics.

Ambitious Goals and Quirky Ultimatums

Musk’s compensation comes with performance-based vesting, meaning he only cashes in if Tesla meets mind-boggling growth benchmarks. It’s the sort of pay-for-performance scheme that leaves many CEOs clutching their calculators and investors reaching for popcorn. Musk has previously described his need for 20% control of Tesla as an existential requirement for staying with the company—put less delicately, “if I don’t get my way, I’ll take my ball (and robots, and AI) elsewhere”.

In the end, the market itself seemed to toast the outcome, with Tesla’s shares climbing 2% on the news—perhaps already pricing in the company’s imminent acquisition of New Jersey, or at the very least the increasingly plausible robot apocalypse.

The Last Word

Whether this pay plan will be remembered as genius capitalist motivation or a billionaire’s fever dream is a tale for future historians (or the Optimus robots themselves). For now, however, the message from Tesla’s board to Musk could not be clearer: Reach the stars, but don’t forget to take the shareholders (and the company’s stock price) along for the ride.

The Sources

by Vista Partners LLC November 6, 2025

S&P 500, Dow, Nasdaq Slide Amid Labor Market Woes and Government Shutdown Fears – Nov. 6, 2025 -( $DDOG $INTG $LLY $MODD $NOK $RIO $VIX Rise!)

Wall Street ended Thursday, November 6, 2025, sharply lower as surging volatility and renewed skepticism over tech valuations sent both large and small caps reeling. The Dow Jones Industrial Average finished down 0.84% at 46,912.30, the S&P 500 lost 1.1% to close at 6,720.32, and the Nasdaq Composite fell 1.9% to finish at 23,053.99. The Russell 2000 slipped to 2,418.82, -1.86% reflecting continued risk aversion among investors.

Macroeconomic Reports, Fed Update, Shutdown & Tariffs

Market sentiment was weighed down by fresh signs of weakness in the labor market and sluggish ISM services data, signaling the economy’s expansion may be faltering. Treasury yields pulled back—10-year notes ending at 4.089%—as investors priced in rising recession risks and a still-inverted yield curve, while the came down to 3.568%. The Federal Reserve made no new rate move today, with observers expecting the next FOMC decision later this month; rate cut hopes remain modest as the government shutdown continues unresolved into a fifth week. The Supreme Court also heard fresh arguments on Trump-era tariffs, hinting at a possible easing, though no final word yet—manufacturers remain on edge. The US government shutdown stretched deeper into the month, choking off full macroeconomic visibility.

Notable Stock Performances for Key Names

Eli Lilly (LLY): Closed at $937.44, +1.26% with shares holding up on GLP-1 optimism after agreeing to lower the their prices with the US Government.
NVIDIA: Down sharply to $188.08, -3.65% as a broad tech rout punished AI leadership stocks.
Nokia: (NOK) Ended at $6.95, +.88% moving somewhat sideways in an otherwise volatile session.
Amazon: Closed at $253.04, -2.86% lower as investors rotated out of growth.
Apple: Fell -.145 to $269.77 amid general tech selling pressure.
Tesla: Down 3.54% to $445.91, tracking broader electric vehicle and growth stock weakness.
Broadcom: Settled at $355.59, -.94% also under pressure as chip names fell with sentiment.
Meta: Dropped to $618.94, -2.67% with large-cap tech unable to escape the day’s downdraft.
McDonald’s: Went on a diet closing at $298.41, -2.38% however strong Q3 international sales supporting the golden arches.
Rio Tinto (RIO): Ended at $69.27, +.30% as global commodity markets remained subdued, however it has jumped 4.04% to $72.07 in the aftermarket
Oracle: Down 2.60% to $243.80.
Intel: Closed at $37.34, -2,97% pressured by cyclical headwinds in hardware.
Opendoor: Ended at $6.56 mirroring broad risk-off. Today, Opendoor Technologies Inc. (Nasdaq: OPEN) announced a special dividend distribution of warrants to holders of the Company’s common stock as of 5:00 p.m. New York City time on November 18, 2025 (the “Record Date”). The goal is simple: if management gets performance-based upside, shareholders should too – these warrants help achieve that. This program is intentionally structured as a new playbook for public-company alignment. Each registered shareholder as of the Record Date will receive three series of warrants – Series K, Series A, and Series Z – one (1) warrant of each series for every thirty (30) shares of the Company’s common stock held, rounded down to the nearest whole number. The details of these warrants are provided at this link and they plan for them to be listed and fully tradable. You can sell them on day one, or hold them and ride with the company as they rebuild the company.
Datadog, Inc. (DDOG, $190.82, +23.13%), the monitoring and security platform for cloud applications, reported that their third quarter revenue grew 28% year-over-year to $886 million, robust growth of larger customers, with about 4,060 $100k+ ARR customers, up from about 3,490 a year ago, & that they reached a milestone of over 1,000 integrations on the Datadog unified platform.

Market Barometers: Volatility, Commodities, and Crypto

VIX (CBOE Volatility Index): Rose 8.27% to 19.50, with anxiety clearly back on center stage.
Gold: Steady near $3,986.40/oz as traders sought a defensive posture.
Silver: Traded around $47.86/oz, fairly flat for the day.
Oil (WTI): Ended at $59.53/bbl, reflecting persistent supply questions.
Bitcoin: Traded near $101,167 with a 2.42% drop on the day, remaining highly volatile.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $5102, +3.40%), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR) and M2i Global, Inc. (MTWO, $.1025, +2.50%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.33, +.07%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.29, +2.11%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

Sources

by Vista Partners LLC November 6, 2025

The Robot Uprising Will Be Televised: Apple’s Home Bots Vs. Tesla’s Factory Force -( $AAPL $TSLA $DIA $SPY )

Apple (AAPL) is setting the stage for a future that might make even Siri do a double-take: by 2040, analysts at Morgan Stanley (MS) predict Apple could rake in an astonishing $133 billion a year from humanoid robotics, a number robust enough to dethrone Macs and possibly send Tim Cook into spontaneous robot dance mode. If that wasn’t futuristic enough, the race for droid supremacy has Tesla (TSLA) rolling out its own ambitious “Optimus” robots, and CEO Elon Musk—never one to shy away from sci-fi—believes Optimus could compose 80% of Tesla’s value in years ahead, leaving electric cars as a sideshow act at the Musk family robot talent show.

Apple’s Humanoid Aspirations

Apple’s robotics platform is projected to revolutionize how users interact with their homes, offices, and maybe even the family pet. The company’s first product—expected as early as 2027—will be a motorized tabletop hub that glides across surfaces, tracking users and handling daily tasks with the cool efficiency of an over-caffeinated Roomba. With a forecasted 9% slice of the global robotics market, Apple may soon join its iPhone, Mac, and services divisions as a fourth pillar of revenue. Under Morgan Stanley’s optimistic scenario, Apple’s robotics revenue could surge past $300 billion, making the company’s robot division only slightly less lucrative than selling actual iPhones (and much less likely to be dropped in a toilet).

Tesla’s Robot Revolution

Meanwhile, Tesla isn’t just charging up batteries—it’s training robots to moonwalk through factories. Musk has announced plans for thousands of Optimus units in Tesla factories this year, scaling to millions as soon as possible. If Tesla’s vision pans out, robot workers will become as common in manufacturing as memes in Musk’s Twitter feed. However, some skeptics—possibly humans in disguise—note that humanoid shapes aren’t always the most efficient for factory work, though Musk is betting his AI chips on making Optimus the world’s most versatile bipedal intern.

The Great AI Droid-Off

The battle lines are drawn: Apple brings engineering prowess, ecosystem integration, and a flair for waiting until competitors beta-test embarrassment out of their products, while Tesla touts breakneck innovation and a willingness to redefine the rules (and the workplace break room). Both companies seem to agree that “embodied AI”—robots with personalities coded somewhere between Jeeves and Jarvis—will transform labor, leisure, and maybe even rock-paper-scissors tournaments.

The Market Stakes

Morgan Stanley envisions a $5 trillion humanoid robot sector by 2050, with millions of units working alongside humans. As costs decline from $200,000 to as little as $10,000 a year, soon humanoid assistants could be doing everything except explaining why your WiFi is slow. Apple and Tesla are prime candidates to dominate a world where robots fetch coffee, fold laundry, and—if Musk is correct—occasionally perform surgery (pending FDA approval and a good bedside manner).

In Silicon Valley’s newest arms race, one thing is clear: the robots are coming, and they might just have better stock options, snazzier startup routines, and a mysterious preference for wireless charging stations over coffee breaks.

If Morgan Stanley’s predictions hold, soon investors may wonder: Will Siri and Optimus ever collaborate for a “Dancing with the Droids” spin-off? Let’s just hope neither learns how to short stocks.

The Sources

by Vista Partners LLC November 6, 2025

Pharma Disruption: Lilly, Novo Nordisk Price Cuts Reshape Obesity Care & Modular Medical’s Diabetes Tech Milestone -( $LLY $NVO $MODD )

This week, the pharmaceutical world witnessed a seismic shift as Eli Lilly (LLY) and Novo Nordisk (NVO) entered the headlines with deals to make their coveted obesity medications far more affordable for Americans. Responding to the administration’s call to rein in soaring drug costs, both companies agreed to slash prices across Medicare, Medicaid, and direct-to-consumer channels, making blockbuster drugs like Wegovy and Zepbound newly accessible for a broad swath of patients.

Historic Price Cuts and Expanding Coverage

The agreement means GLP-1 drugs—previously out of reach for most patients with monthly price tags from $1,000 to $1,350—will soon be available for as little as $145 per month for Medicare beneficiaries and as low as $149 per month for oral versions at the lowest strengths, pending FDA approvals. Patients paying cash or using the newly introduced TrumpRx.gov platform will also see sharply reduced costs. Medicare and Medicaid programs will cover these treatments for the first time, promising to ease the financial burden and laying the groundwork for increased insurer uptake nationwide.

Impact on American Patients and the Market

These deals are expected to unlock access for millions, especially those struggling with comorbidities tied to obesity. Analysts forecast that the expanded reach could result in significant public health benefits, with one estimate suggesting Americans could collectively lose up to 125 million pounds over the next year if coverage and uptake are robust. While some Medicare recipients will face $50 monthly copays, the net effect is a dramatic increase in affordability and access for seniors and lower-income individuals, with Medicaid programs also invited to participate at discounted rates, subject to state approval.

Strategic Moves and Political Ripples

Politically, these deals represent not just a victory for patients, but also a masterstroke for the White House, which has been vocal about lowering drug prices. Drugmakers will benefit from tariff exemptions and fast-tracked regulatory processes, balancing public relations wins with new regulatory relief. Equity analysts note that shares of both firms rose in response to the news, reflecting investor confidence that increased market penetration will more than offset narrower margins.

Modular Medical Sets the Stage for Q1 2026

Not to be outdone in the innovation department, Modular Medical (MODD) used this week to announce its own milestone: successful validation of the Pivot Controller Line for human-use production. The Pivot—a 3 milliliter, tubeless, removable patch pump—is aimed at adults in the “almost-pumper” crowd who find traditional insulin pumps too complicated or expensive. With FDA clearance still in the wings, CEO Jeb Besser stressed that Modular’s scalable manufacturing capacity now stands ready for a Q1 2026 launch, pending final regulatory approval.

Modular’s Market Ambitions and Risks

With its focus on enhanced simplicity and affordability, the Pivot targets a $3 billion market of adults who have yet to embrace pump therapy. The company’s validation is seen as a critical differentiator in the patch pump space, but industry analysts caution that regulatory and market acceptance remain as tall as ever for any device in this sector.

Key Industry Takeaways

Eli Lilly and Novo Nordisk have cut prices for obesity drugs, dramatically expanding coverage for seniors and low-income patients via Medicare and Medicaid—plus direct-to-consumer options.nbcnews+1
Reduced monthly prices—now as low as $145 and $149—represent a seismic change from previous $1,000+ costs, bringing formerly exclusive treatments within reach for millions.cnbc+2
Modular Medical’s validation of the Pivot Controller Line positions the company for a Q1 2026 launch, targeting “almost-pumpers” and hoping to crack open a $3 billion diabetes care market, provided the FDA gives its blessing.

The Sum

As pharmaceutical giants write new chapters in drug pricing and nimble device makers hustle for regulatory runway, one thing is certain: for patients, accessible healthcare innovation is fast becoming more reality than rhetoric—with investors and competitors paying close attention to every twist in the plot.

The Sources

by Vista Partners LLC November 6, 2025

An Apple & Google Billion-Dollar AI Alliance: How It Could Change Mobile Search Forever -( $AAPL $GOOG $SPY $DIA )

Apple (AAPL) is reportedly nearing a landmark agreement to pay Google roughly $1 billion each year—apparently a bargain for a company whose market cap now eclipses the GDP of Denmark—to power the next generation of Siri using Google’s colossal AI model. This deal, undertaken with a confidentiality reminiscent of a G7 summit, marks a new chapter in Silicon Valley’s favorite corporate frenemy relationship, complete with courtroom drama, regulatory intrigue, and a dash of strategic one-upmanship worthy of any midday boardroom soap opera.

Siri’s Glow-Up: Powered by Google Brain

Apple, long content to let Siri answer questions with all the subtlety of a well-meaning but clueless uncle, has finally acknowledged that perhaps Google’s 1.2 trillion-parameter AI could teach the voice assistant new tricks—or at least, help it avoid confusing “weather in Paris” with “party in Weimar Republic”. For Google, the deal is more than just another cash injection—it’s a crowning endorsement from the very company that built its brand on the premise of “Think Different”. If you can’t beat ‘em, let ‘em run your voice assistant.

Antitrust Tango: When $20 Billion Is Just a Footnote

For years, Google’s payments to Apple (now estimated at $20 billion annually just for search engine default privilege) have been the subject of antitrust scrutiny heavier than a typical Friday in Brussels. Federal courts, after much deliberation, have waved the deal through for now—though only on one-year contracts, giving Apple annual leverage to extract increasingly fanciful terms. The arrangement contributes a handsome chunk to Apple’s Services revenue, a division growing faster than most portfolio managers’ patience at regulatory hearings.

The Implications: Wall Gardens and Competitive Weeding

Apple’s classic “walled garden” ecosystem, where the only way out is through another paid subscription, finds reinforcement in this partnership. Meanwhile, Google gets privileged access to Apple’s global user base, which drives as much as half of its mobile search revenue—proving once again that, in tech, successful co-dependency beats rivalry any day. The upshot: regulators remain perplexed, competitors remain outside looking in, and investors watch Alphabet stock jump at every fresh headline.

The Real AI Upgrade

If Apple’s internal teams are crestfallen over not developing a competitive AI in-house, they can take solace in the fact that at least Siri won’t be recommending “iPhone cleaning fluid” for existential crises anymore. For Google, handing over AI smarts might be the closest thing to buying new friends this side of an elementary school playground. Somewhere, Alexa is quietly wondering if it’s time to start sending résumés.

In sum, the Apple-Google pact is emblematic of modern tech strategy—a marriage of convenience, lavishly funded, and more closely observed by regulators than a Wall Street analyst counting free muffins in an earnings call. Let the search—and the sophisticated AI banter—continue.

Sources

[1] Apple Nears Deal to Pay Google Roughly $1 Billion a Year for Siri AI Model https://finance.yahoo.com/news/apple-nears-deal-pay-google-193449127.html
[2] Apple nears deal to pay Google $1B annually to power new Siri, report says https://finance.yahoo.com/news/apple-nears-deal-pay-google-203747696.html
[3] Apple dodged a $20 billion hit, thanks to Google antitrust ruling https://finance.yahoo.com/news/apple-dodged-a-20-billion-hit-thanks-to-google-antitrust-ruling-163056806.html
[4] Apple, Google Agreed to ‘Defend’ Search Deal From Regulators https://finance.yahoo.com/news/apple-testify-sees-no-deploy-090000841.html
[5] Apple Nears $1 Billion-a Year Deal to Use Google AI for Siri https://www.bloomberg.com/news/articles/2025-11-05/apple-plans-to-use-1-2-trillion-parameter-google-gemini-model-to-power-new-siri
[6] Alphabet stock jumps after report of Apple’s plans to use Google AI … https://uk.finance.yahoo.com/news/alphabet-stock-jumps-report-apple-195008167.html
[7] Apple-Google Search Deal Stability Could Be a Game Changer for … https://finance.yahoo.com/news/apple-google-search-deal-stability-120646516.html
[8] Apple’s $20 Billion Search Payment Survives: Here’s What It Means … https://finance.yahoo.com/news/apples-20-billion-search-payment-072500497.html
[9] Would You Still Use Google if It Didn’t Pay Apple $20 Billion to Get … https://www.wired.com/story/google-pay-apple-20-billion-to-get-on-your-iphone/
[10] Google’s $20 Billion Annual Payment to Apple for Default Search … https://rocketclicks.com/industry-news/google-twenty-billion-dollar-payment-apple-search/
[11] Apple Snoozed, so Now It Might Lose Google as Its Default Search … https://www.reddit.com/r/technology/comments/1jk993u/apple_snoozed_so_now_it_might_lose_google_as_its/
[12] Apple’s $20 Billion Risk: What Happens if Google’s Payments … https://www.cmswire.com/digital-experience/apples-20-billion-risk-what-happens-if-googles-payments-disappear/
[13] Google’s Payments to Apple Reached $20 Billion in 2022, Cue Says https://www.bloomberg.com/news/articles/2024-05-01/google-s-payments-to-apple-reached-20-billion-in-2022-cue-says
[14] Perplexity Finance – Quotes, Forecasts, News, Charts, and More https://www.perplexity.ai/finance/AAPL
[15] Alphabet stock jumps after report of Apple’s plans to use Google AI for Siri https://finance.yahoo.com/news/alphabet-stock-jumps-report-apple-194813463.html
[16] Apple’s reported Google deal, Teva & Axon post-earnings moves https://finance.yahoo.com/video/apples-reported-google-deal-teva-212128073.html
[17] Google paying Apple $3 billion to remain default search – Bernstein https://www.cnbc.com/2017/08/14/google-paying-apple-3-billion-to-remain-default-search–bernstein.html
[18] Google, Epic Games Strike Comprehensive Deal In Long-Running … https://stocktwits.com/news-articles/markets/equity/google-epic-games-strike-comprehensive-deal-in-antitrust-case/cL2qarZREG3
[19] Google Settles Epic Lawsuit, Cuts Android Store Fees to 9-20% https://www.techbuzz.ai/articles/google-settles-epic-lawsuit-cuts-android-store-fees-to-9-20
[20] Epic Games CEO calls Google’s antitrust settlement a win for … https://finance.yahoo.com/news/epic-games-ceo-calls-google-144935317.html
[21] The Legal Analyst In Google’s Corner – AdExchanger https://www.adexchanger.com/adexchanger-talks/the-legal-analyst-in-googles-corner/

by Vista Partners LLC November 6, 2025

Solid Power Plugs in with Samsung and BMW: Solid-State Battery Race Powers Up -( $SLDP $SPY )

Solid Power’s (SLDP, $8.51, Up +350.26% YTD) third-quarter story reads a bit like an Arthur Miller play staged in Silicon Valley: heady ambitions, strategic names stepping onto the set, and the comforting aroma of liquidity—punctuated by the occasional plot twist in quarterly revenue. In its new act, the Colorado-based battery upstart has drawn Samsung SDI and BMW onto center stage, forming a transatlantic trio determined to move solid-state batteries from “almost there” to something you can actually buy in a dealer’s forecourt. The goal? To make electric vehicles both safer and as energized as a triple espresso shot.

“A Little Chemistry—with Samsung and BMW”

The latest Joint Evaluation Agreement hands Samsung SDI Solid Power’s sulfide-based solid electrolyte, which the Korean giant uses to assemble what can only be described as next-gen battery cells. BMW, meanwhile, gets the fun job of wrapping those cells into modules and packs, ready for vigorous German engineering scrutiny. It’s a marriage of convenience and technical savvy: Samsung does scale, Solid Power brings the sizzle (quite literally, since solid-state tech removes the flammable bits), and BMW aims to toss the finished product under the hoods of test vehicles, pushing us all toward the long-promised “electric future” with fewer fire drills.

Let’s not gloss over Samsung and BMW’s long-standing partnership, which has now acquired an American twist. For years, the duo has mixed batteries and Bavarian automotive flair. With Solid Power in the triumvirate, the mission is to beat lithium-ion on safety and energy density, giving future BMW drivers longer ranges and, perhaps, a little less range anxiety at dinner parties.

Financials: The “Solid” in Solid Power

Of course, even the most electrifying narrative needs good bookkeeping. Solid Power’s Q3 revenue slipped to $4.6 million—down from $7.5 million the previous quarter—eliciting a 12% after-hours stock drop. Yet, for those inclined to look at the silver lining (or sulfide, in this case), the company’s year-to-date revenue hit $18.1 million, $2.4 million above the same period last year. Losses remain substantial, but so does the liquidity: $300 million in cash, fortified by recent share sales and grants. In startup land, that’s the financial equivalent of wearing a raincoat in a thunderstorm—hardly a guarantee, but infinitely preferable to the alternative.

The Road Ahead: Solidifying Hype

Solid Power’s batteries, if and when they clear validation, promise 15–35% cost advantages over incumbent lithium-ion cells, along with fewer meltdowns and lower weight—so long as all those layers of chemistry cooperate. Meanwhile, the company’s R&D spend remains brisk, but with partners like Samsung and BMW, they appear to have bought themselves both time and relevance. For now, think of this as Battery Hamlet: lots of drama, big names, and a plot everyone’s hoping won’t end in a fire (literal or financial).

In short: Solid Power may not yet be powering your neighbor’s BMW, but it’s putting on quite the show in the race to electrify the road—in three acts, with occasional comic relief and a solid dash of engineeringneering suspense.

A Slimmer Strategy

Why the Rush?

Novo’s Burning Calories

Pipeline: More Than Just Empty Calories

Shareholder Weigh-In

The Sources

Major Index Performance

Macroeconomic Reports

Index Movers: Sectors and Stocks

Welcomed IPOs

Tariffs and Trade

Yield Curve, Rates, and Fed Announcements

Gold, Silver, Oil, and Crypto

Conclusion

VP Watchlist Updates

The Sources

Oracle Bets Big, Again

Financial Alchemy and Syndicate Swagger

AI Boom: Promise and Risk

Market Reaction: Stocks, Swaps, and Sarcasm

The Sources

Financial Highlights

Market Reaction and Outlook

Strategic Moves and Sophisticated Punchlines

The Sources

The Magnitude of Musk’s Windfall

Boardroom High Wire, Shareholder Showmanship

Ambitious Goals and Quirky Ultimatums

The Last Word

The Sources

Macroeconomic Reports, Fed Update, Shutdown & Tariffs

Notable Stock Performances for Key Names

Market Barometers: Volatility, Commodities, and Crypto

VP Watchlist Updates

Sources

Apple’s Humanoid Aspirations

Tesla’s Robot Revolution

The Great AI Droid-Off

The Market Stakes

The Sources

Historic Price Cuts and Expanding Coverage

Impact on American Patients and the Market

Strategic Moves and Political Ripples

Modular Medical Sets the Stage for Q1 2026

Modular’s Market Ambitions and Risks

Key Industry Takeaways

The Sum

The Sources

Siri’s Glow-Up: Powered by Google Brain

Antitrust Tango: When $20 Billion Is Just a Footnote

The Implications: Wall Gardens and Competitive Weeding

The Real AI Upgrade

Sources

“A Little Chemistry—with Samsung and BMW”

Financials: The “Solid” in Solid Power

The Road Ahead: Solidifying Hype

Sources

Your Guide To Staying Informed In The Markets